Method for vector delivery

Abstract

Provided is a lentiviral vector for delivery to the brain for use in treating a neurological condition, wherein the lentiviral vector is delivered directly to the brain by delivering the lentiviral vector via six or fewer tracts per hemisphere, at a single deposit point per tract.

1 . A lentiviral vector for delivery to the brain for use in treating a neurological condition, wherein a composition comprising the lentiviral vector is delivered directly to the brain by continuous infusion using a cannula and wherein between 10-600 μL of the vector composition is delivered per tract at a flow rate of at least 2 μL/min. 
     
     
         2 . The lentiviral vector according to  claim 1 , wherein the cannula is of sufficiently narrow bore to prevent substantial backflow of the vector composition. 
     
     
         3 . The lentiviral vector according to  claim 1 , wherein a constant flow rate is maintained during infusion of the lentiviral vector. 
     
     
         4 . The lentiviral vector according to  claim 1 , wherein the flow rate is increased during infusion of the lentiviral vector. 
     
     
         5 . The lentiviral vector according to  claim 1 , which is an equine infectious anaemia virus (EIAV) vector. 
     
     
         6 . The EIAV vector according to  claim 5 , which comprises nucleotide sequences encoding Tyrosine Hydroxylase, GTP-cyclohydrolase I and Aromatic Amino Acid Dopa Decarboxylase. 
     
     
         7 . The lentiviral vector according to  claim 1 , wherein the lentiviral vector is delivered via a single tract per hemisphere. 
     
     
         8 . The lentiviral vector according to  claim 7 , wherein the infusion has a volume of about 50 μL. 
     
     
         9 . The lentiviral vector according to  claim 1 , wherein the flow rate at which the vector is delivered is between 2-4 μL/min. 
     
     
         10 . The lentiviral vector according to  claim 1 , wherein the flow rate at which the vector is delivered is about 3 μL/min. 
     
     
         11 . The lentiviral vector according to  claim 1 , wherein the lentiviral vector is delivered using a cannula with a bore equivalent to or narrower than 28 gauge. 
     
     
         12 . The lentiviral vector according to  claim 1 , for treating Parkinson's disease. 
     
     
         13 . A method for treating a neurological disorder in a subject which comprises the step of administrating a lentiviral vector as defined in any preceding claim to the subject, in which method a composition comprising the lentiviral vector is delivered directly to the brain by continuous infusion using a cannula and wherein between 10-600 μL of the vector composition is delivered per tract at a flow rate of at least 2 μL/min. 
     
     
         14 . A method for improving the distribution volume of a lentiviral vector in the putamen when administered directly to the brain of a subject, wherein the method comprises continuous infusion of a composition comprising a vector using a cannula, wherein between 10-600 μL of the vector composition is delivered per tract at a flow rate of at least 2 μL/min. 
     
     
         15 . A kit for delivering the lentiviral vector as defined in  claim 1  directly to the brain of the subject, which comprises one or more cannulas. 
     
     
         16 . The kit according to  claim 15 , wherein the cannula(s) is/are pre-filled with the lentiviral vector at a volume of between 10 and 600 μL. 
     
     
         17 . The kit according to  claim 15 , which comprises one or more cannula(s) for delivery of the vector, wherein the cannula(s) is/are 28 gauge or narrower.